A phase II study of tamoxifen in ovarian cancer.
A phase II study of tamoxifen was conducted in 22 patients with stage III and IV ovarian cancer who had failed chemotherapy and who had evaluable disease. Tamoxifen was administered at a dose of 20 mg twice daily continuously until evidence of progression. Twenty-one patients had progression of disease within 3 months and one patient had stable disease for 6 months. There were no objective responses to this treatment.
Slevin
M L
ML
Harvey
V J
VJ
Osborne
R J
RJ
Shepherd
J H
JH
Williams
C J
CJ
Mead
G M
GM
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013629:Tamoxifen / Q000627:therapeutic use*
D013629:Tamoxifen